Abstract
One of the most difficult tasks in the evaluation of a medicine is whether it causes a particular rare and unusual (idiosyncratic) adverse effect. Such causality assessments are sometimes done by drug de-challenge and re-challenge. When the adverse effect is potentially serious, there is clearly an important decision to be made as to whether the re-challenge is justifiable and hence ethical. The recent controversy about the potential cardiotoxicity of fexofenadine, the fatalities associated with penicillin re-challenge and the fatalities associated with abacavir re-challenge highlight some of the potential serious risks of drug re-challenge. The associated important ethical issues are discussed. In particular, there is the need to ensure respect for the patient and to consider the scientific and social value of the re-challenge. A framework for evaluating and assessing the appropriateness of a particular drug re-challenge is proposed in the light of recent as well as long-standing discussions of drug re-challenge, patient informed consent and the ethics of human experimentation, in general. It is suggested that a drug re-challenge should be approached with the same rigour and standards of documentation as are currently required of clinical trials. Given the potential conflicts of interest inherent with any drug study, it is argued that the safeguards, as may be provided by scrutiny by an ethics committee, are necessary for a drug re-challenge. For the investigator contemplating the conduct of a drug re-challenge we would recommend the following: (i) a careful risk-benefit assessment as part of the decision-making process; (ii) careful scientific preparation, including appropriate expert support and emergency back-up facilities, if re-challenge is deemed necessary; (iii) the writing of a detailed protocol for independent approval and for safeguarding all concerned; and (iv) meticulous record keeping.
Similar content being viewed by others
References
Stephens MDB. Detection of new adverse drug reactions. 3rd ed. Basingstoke: Macmillam Press, 1992
Li Wan Po A, Kendall MJ. Causality assessment of adverse drug effects: when is rechallenge ethically acceptable [letter]? Lancet 1999; 354(9179): 683
Pinto YM, van Gelder IC, Heeringa M, et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine [letter]. Lancet 1999; 353(9157): 980
Faber TS, Zehender M Just H. Drug-induced torsade de pointes. Drug Saf 1994; 11: 463–76
Li Wan Po, Zhang WY. What lessons can we learn from the withdrawal of mebifradil from the market [letter]? Lancet 1998; 351: 1829–30
Simons FE, Bergma NJ, Watson WT, et al. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996; 98: 1062–4
Pinto YM, van Gelder IC, Crijns JGM, et al. Causality assessment of adverse drug effects: when is rechallenge ethically acceptable [letter]? Lancet 1999; 354(9179): 683
Pumphrey RSH, Davis S. Under-reporting of antibiotic anaphylaxis may put patients at risk. Lancet 1999; 353: 1157–8
Anne S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol 1995; 74: 167–70
Adkinson Jr NF. Beta-lactam cross-reactivity. Clin Exp Allergy 1998; 28(Suppl 4): 37–40
Salkind AR, Cuddy PG, Foxworth JW. Is this aptient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. JAMA 2001; 285: 2498–2505
Odawara M, Tamaoka A, Yamashita K. Ginkgo Biloba. Neurology 1997; 48: 789
Vale S. Subarachnoid haemorrhage associated with Ginkgobiloba [letter]. Lancet 1998; 352: 36
Chung KF, Dent G, McCusker M, et al. Effect of ginkgolide mixture (BN 52063) in antaginising skin and platelet responses to platelet activating factor in man. Lancet 1987; I: 248–51
Rowin J, Lewis SL. Spontaneous blateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46: 1775–6
Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997; 336: 1108
Skogh M. Extracts of Ginkgo biloba and bleeding or haemorrhage [letter]. Lancet 1998; 352: 1145–6
Vale S. Extracts of Ginkgo biloba and bleeding or haemorrhage [letter]. Lancet 1998; 352: 1145–6
Committee for Proprietary Medicinal Products European Public Assessment Report (EPAR) on Ziagen 1. London: European Medicines Evaluation Agency, 2000 Jan 20
Atkinson P, Joubert G, Barron A, et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric patients. Lancet 1995; 345: 894–6
Baruch Y, Weitzman E, Markiewicz W, et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. Transplant Proc 1996; 4: 2250–1
Whitington P, Alonso EM, Piper JB. Pediatric liver transplantation. Semin Liver Dis 1994; 14: 303–17
Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000; 283: 2701–11
AIDS, the unbridgeable gap. Lancet 1998; 351: 1825
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li Wan Po, A., Kendall, M.J. Causality Assessment of Adverse Effects. Drug-Safety 24, 793–799 (2001). https://doi.org/10.2165/00002018-200124110-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200124110-00001